1 GLUCOWATCH ® G2™ BIOGRAPHER H. PETER CHASE, MD I)INTRODUCTION II)ACCURACY DATA III) HOME PILOT TRIAL IV) DIRECNET STUDY GROUP V) SUMMARY.

Slides:



Advertisements
Similar presentations
Down Alert Function of the GlucoWatch® G2 TM Biographer (GW2B) During Insulin- induced Hypoglycemia in Children Eva Tsalikian 1, Craig Kollman 2, Rosanna.
Advertisements

Monitoring diabetes Diabetes Outreach (March 2011)
Continuous Glucose Monitoring Thomas Repas D.O. Diabetes, Endocrinology and Nutrition Center, Affinity Medical Group, Neenah, Wisconsin Member, Inpatient.
INTRODUCTION TO CONTINUOUS GLUCOSE MONITORS
Journal Club Usha Niranjan PICU. Rationale 2 x cases of severe dehydration with metabolic acidosis –requesting for HDU management –as given 40mls/kg fluid.
Glycemic Control in Acutely Ill Patients Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice President for.
Continuous Glucose Monitoring. Diabetes Management Evolution Insulin Delivery Glucose Monitoring 2000 First CGM system 2006 Paradigm REAL- Time, combining.
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
Diabetes Control in Youth: The American Experience Georgeanna J. Klingensmith, MD Keystone Colorado July 2008.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Diabetes Update: Living Life after Lente
1 INTRODUCTION TO CONTINUOUS GLUCOSE MONITORS H. Peter Chase, MD Vicky Gage, RN, CDE Laurel Messer, RN, CDE Susie Owen, RN, CDE Sally Sullivan, RN, CDE.
1 Progress Towards an Artificial Pancreas for T1D WILLIAM TAMBORLANE, MD Chief of Pediatric Endocrinology, Yale University, Deputy Director, Yale Center.
Suhyla Alam (Eastern Virginia Medical School), Amy West, Maura Downey, Jane EB Reusch, Kristen Nadeau University of Colorado Denver and Children’s Hospital.
Accuracy of the FreeStyle Navigator ™ Continuous Glucose Monitor Diabetes Research in Children Network Larry Fox, 1 Roy Beck, 2 Stuart Weinzimer, 3 Katrina.
GLUCOSE TESTING USING THE TRUEtrack GLUCOMETER
Diabetes Research in Children Network (DirecNet) Outpatient Pilot Study to Evaluate the GlucoWatch® G2 TM Biographer in the Management of Type 1 Diabetes.
Limitations of Statistical Measures of Error in Assessing the Accuracy of Glucose Sensors Craig Kollman1, Darrell Wilson2, Tim Wysocki3, Rosanna Fiallo-Scharer4,
INSULIN THERAPY IN TYPE 1 DIABETES
Practical Aspects of Continuous Glucose Monitoring 2008 Rosanna Fiallo-Scharer, MD Laurel Messer, RN, BSN, CDE Barbara Davis Center for Childhood Diabetes.
Diabetes Research in Children Network (DirecNet) Outpatient Pilot Study to Evaluate the Feasibility of Computer-Based Data Acquisition and Transmission.
Sugar control in Critical care unit Senior clinical pharmacist : Lihua Fang Koo Foundation Cancer Center.
A 5-center CRC-based Study of the Accuracy of the GlucoWatch® G2 TM Biographer in Children and Adolescents with Type 1 Diabetes Darrell Wilson 1, Bruce.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
Mealtime Glycemic Excursions in Pediatric Subjects with Type 1 Diabetes: Results of the Diabetes Research in Children (DirecNet) Accuracy Study Study Group.
Abstract Background: As part of a study to evaluate the accuracy of the GlucoWatch ® G2 TM Biographer and the Continuous Glucose Monitoring System (CGMS.
Diabetes Control and Complications Trial (DCCT) Results indicate that most youth with T1DM should be treated intensively in order to reduce the risk of.
Background: DirecNet Diabetes Research in Children Network NIH funded collaborative study group 5 clinical centers, central laboratory, coordinating center,
The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Brief Protocol Training NIH-NINDS U01 NS NETT CCC U01 NS NETT SDMC U01 NS
Diabetes Research in Children Network Pilot Study of the Navigator TM Continuous Glucose Monitoring System in Children with Type 1 Diabetes: Safety, Tolerability,
DIABETES MELLITUS IN CHILDREN. Blood glucose Apart from transient illness-induced or stress-induced hyperglycemia, a random whole-blood glucose.
Event-Based Assessments of Sensor Accuracy during Exercise-Induced Reductions in Glucose in Children with Type 1 Diabetes Craig Kollman, 1 Darrell Wilson,
Impact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes (T1DM) Eva Tsalikian 1 ; Roy Beck 2 ; Peter Chase 3 ; Tim Wysocki 4 ;
Gestational Diabetes Testing Paradigms in a Rural Office November 7, 2014.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Internet-based pilot study comparing low fat with high fat evening snacks in children and adolescents with Type 1 Diabetes using continuous glucose monitoring.
Use of The FreeStyle Navigator TM Continuous Glucose Monitoring System in Children on Glargine- based Multiple Daily Injection Therapy Stuart Weinzimer.
Use of the FreeStyle Navigator ™ Continuous Glucose Monitoring System in Children with Type 1 Diabetes Diabetes Research in Children Network L. A. Fox,
Lack of Effectiveness of the GlucoWatch Biographer (GW2B) in Altering Glycemic Control in Children with Type 1 Diabetes H. Peter Chase 1, Roy Beck 2, William.
A Comparison of the Original vs. Modified Continuous Glucose Monitoring System (CGMS™) Sensor During Hypoglycemia in the Diabetes Research in Children.
Utility of CGMS as a Measure of Glycemic Control in Children with Type 1 Diabetes (T1DM) Rosanna Fiallo-Scharer, MD for.
Reliability of two indices of the biologic variability in glycosylation among children and adolescents with T1DM Darrell M Wilson 1, Rosanna Fiallo-Scharer.
Evaluation of Factors Affecting CGMS Calibration Bruce Buckingham, 1 Craig Kollman, 2 Roy W Beck, 2 Andrea Kalajian, 2 Rosanna Fiallo-Scharer, 3 Michael.
Accuracy Study of the Medtronic Minimed Continuous Glucose Monitoring System (CGMS) and GlucoWatch® G2TM Biographer (GW2B) in Children with Type 1 Diabetes.
Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes Featured Article: Aris Siafarikas, F.R.A.C.P., M.D., Robert J.
Performance of the DCA 2000 ® + Analyzer for Measurement of Hemoglobin A1 c Levels in Children with T1DM in a DirecNet Outpatient Clinical Trial.
An Educational Service from GlycoMark
Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,
 Provide a high level overview of diabetes head to toe.  Discuss the importance of keeping A1Cs under 8.  Identify ways to prevent long-term complications.
Tresiba- insulin degludec
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Intermittent vs Continuous Pulse Oximetry McCulloh R, Koster M, Ralston S, et al.
Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)
DirecNet Study of the Accuracy of the Navigator Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes Darrell Wilson 1,
The Physiological Variations of Plasma Glucose Concentrations in Healthy, Non-Diabetic Children: Use of Continuous Glucose Sensors Nelly Mauras, Roy Beck,
TEMPLATE DESIGN © CONTINUOUS GLUCOSE MONITORING, ORAL GLUCOSE TOLERANCE, AND INSULIN – GLUCOSE PARAMETERS IN ADOLESCENTS.
1 Establishment of Blood Glucose Monitoring System Using the Internet Diabetes Care 27:478–483, 2004 Long-Term effect of the Internet-Based Glucose Monitoring.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
Glycemia Treatment Strategies Used In ACCORD
EndoTool IV Physician User Guide Content Expert:
Clinical Experience of an Iontophoresis Based Glucose Measuring System
Copyright © 2004 American Medical Association. All rights reserved.
Setareh Omran, MD Vascular Neurology Fellow
Clinical Performance.
Components of a CGM record over a 3
Management of Type II Diabetes
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Campbell FM, et al. Pediatr Diabetes. 2018;19(7):1294–1301
PowerPoint 16:9 Screen Ratio Template *
Cumulative mean numbers of confirmed (plasma glucose ≤3
Presentation transcript:

1 GLUCOWATCH ® G2™ BIOGRAPHER H. PETER CHASE, MD I)INTRODUCTION II)ACCURACY DATA III) HOME PILOT TRIAL IV) DIRECNET STUDY GROUP V) SUMMARY

2 GlucoWatch ® G2™ Biographer

3 GlucoWatch ® G2 ™ Biographer (GW2B) Measures interstitial glucose extracted by reverse iontophoresis Requires a single calibration value following the 2-hour warm-up period Glucose readings every 10 minutes for 13 hours Values range from 40 to 400 mg/dL

4 GlucoWatch G2 Biographer INTRODUCTION i) Second generation model (G2B) ii) Warm-up 2 hours  enter BG value iii) Reverse iontophoresis: AAA battery iv) Pulls interstitial fluid (including glucose) into gel discs in Auto Sensor v) Readings as often as every 10 min for up to 13 hrs (max = 76 readings; Ave = 55) v) Readings as often as every 10 min for up to 13 hrs (max = 76 readings; Ave = 55)

5 INTRO: G2B vi) Numerous data integrity checks are performed that monitor environmental factors (temperature, sweating), sensor function, and performance. If the reading fails the data integrity checks, it is skipped because the value may be incorrect. vii) The G2 Biographer averages the reading obtained in the most recent cycle with the reading obtained in the previous 10 minute cycle.

6

7 INTRO: G2B vii) Alarms for: Hypo/hyper-glycemia (level set by user) Hypo/hyper-glycemia (level set by user) Pending low in next minutes Pending low in next minutes Low or drop 30 minutes prior to detection of sweat Low or drop 30 minutes prior to detection of sweat viii) Up or down arrows with change of 9mg/dl

8 INTRO: G2B: Major uses: i) Nocturnal hypoglycemia ii) Postprandial hyperglycemia iii) Hypoglycemic unawareness iv) Gestational diabetes v) Type 2 diabetes vi) Other (e.g. Glycogen Storage Dis.)

9 G2B: Positives: i)Detection of lows – particularly during the night ii) Making aware of post-prandial highs iii) “Watchdog” effect iv) Detecting “patterns” v) ing data to MD or RN

10 INTRO: G2B:Negatives: i)Skipped readings with sweating ii)Not always awakening for alarm iii) Not waterproof iv) Skin itching, blisters, (remove sensor with Unisolve®) (adults > youth) v)Won’t take first calibration (6%) due to sweat, rapid BG change, weak signal vi) Other skipped readings

11 Side Effects No serious skin reactions No other problems Moderate Irritation example Mild Irritation example

12 GlucoWatch Function Sensor calibration – –1 st attempt 94% – –2 nd attempt 2% – –Failed 4% Sensor lifespan* – –≥14.5 hours (Full)81% – –10.0 to 14.5 hours 3% – –6.0 to 10.0 hours 6% – –<6.0 hours10% Of 14,232 possible GW2B measurements – –17% were skipped Excludes sensors stopped early for logistical reasons. DirecNet Data

13 Analyzer Features Analyzer alert settings may differ from Biographer settings Biographer DOWN alerts Trend arrows not shown on Analyzer screen 220 mg/dL 160 mg/dL

14

15

16 Part II: ACCURACY STUDIES IN CHILDREN 1)Eastman RC, Chase HP, Buckingham B, et al. Pediatric Diabetes 3:127, 2002 i)Clinic setting ii)3 First GW Biographers/subject iii) Multiple wear sites iv) Compared to HemoCue® meter

17 ACCURACY STUDIES IN CHILDREN ACCURACY STUDIES IN CHILDREN 2)DirecNet Study Group i)Inpatient ii) 2 – 4 G2Bs/subject iii) Upper and lower arm sites iv) Compared to hospital lab BG

18 ACCURACY STUDIES IN CHILDREN GWB G2B GWB G2B (Pediatric Diabetes)(DirecNet) SettingsClinic (14 Hr)Inpatient (26 Hr) No. Youth 66 (11.9 yrs) 89 (9.9 yrs) Sensors Comparisons ,659 Skipped Readings: 14% 17%

19 ACCURACY STUDIES IN CHILDREN GWB G2B (Pediatric Diabetes)(DirecNet) i)Mean Difference*-17 mg/dl 2.1 mg/dl ii)Absolute Difference**34 mg/dl30.8 mg/dl iii) MARD*** 21% 22% *Mean Difference = Sensor value – Lab value **Absolute Difference= Absolute value of difference **MARD = Mean Absolute Relative Difference = Sensor value – lab value x 100 lab value lab value

20 ACCURACY STUDIES IN CHILDREN GWB G2B GWB G2B (Pediatric Diabetes)(DirecNet) iv) Correlation Coef v) Consensus Error97% 97% Grid (A + B) Grid (A + B) vi) Paired Values 76% 74% within 20% within 20%

21 ACCURACY STUDIES IN CHILDREN:HYPOGLYCEMIA Overnight Hypoglycemia (<70mg/dl) 1)18 episodes by G2B (DirecNet) 2) 10 episodes = Lab glucose matched 8 episodes = not confirmed 8 episodes = not confirmed

BG BG yo on CSII Basal rates had been erased Accidentally put in rates 12 hours off True lows detected by alarm 4/74/84/94/10

23 BG yo on CSII with correct/new basal rates in place HbA1c = 7.4% 4/12 4/13

24 Part III: HOME PILOT STUDY Use of the GlucoWatch Biographer (GWB) in Children with Type 1 Diabetes (T1DM) Chase HP, Roberts MD, Wightman C, Klingensmith G, Garg SK, et al. Pediatrics 111: ,2003. Objective: To determine the usefulness of the GWB for: 1) detection of hypoglycemia 2) improving glucose control in children and adolescents with T1DM in a home environment

25 40 Randomized Study Subjects Age 7-17 years; mean = 12.4 yrsAge 7-17 years; mean = 12.4 yrs Type 1 diabetes 1 yr (mean = 6.3 yrs)Type 1 diabetes 1 yr (mean = 6.3 yrs) HbA1c >8% on 2 occasions during prior 6 monthsHbA1c >8% on 2 occasions during prior 6 months Absence of clinically significant disease or condition that would interfere with participation in the trialAbsence of clinically significant disease or condition that would interfere with participation in the trial No history of severe hypoglycemia for 6 months preceding entry into the trial (many had prior history of severe hypoglycemia >6 months before study)No history of severe hypoglycemia for 6 months preceding entry into the trial (many had prior history of severe hypoglycemia >6 months before study) Willingness to be randomly assigned to standard care or standard care with Biographer monitoring 4 times/weekWillingness to be randomly assigned to standard care or standard care with Biographer monitoring 4 times/week

26 Study Plan Randomization to two treatment groupsRandomization to two treatment groups –standard care in the home environment –standard care in the home environment with GlucoWatch Biographer monitoring Biographer alerts set to 70 and 300 mg/dLBiographer alerts set to 70 and 300 mg/dL Confirmation of alerts by conventional blood glucose monitoringConfirmation of alerts by conventional blood glucose monitoring Both groups: weekly review of SMBG data (±GWB data) and a phone call from HPCBoth groups: weekly review of SMBG data (±GWB data) and a phone call from HPC

27 Outcome Measures HbA1c measured at baseline, and at 1 and 3 months (DCA-2000)HbA1c measured at baseline, and at 1 and 3 months (DCA-2000) Hypoglycemia events determinedHypoglycemia events determined - Biographer alert = 70 mg/dl - Hypoglycemic event = SMBG <70 mg/dl SurveysSurveys –Fear of Hypoglycemia –Quality of Life (DCCT)

28 GWB: HOME USE Week #Uses/wk %Hi BG* %Lo BG* *GWB readings

29 Frequency of Hypoglycemia Home Meter Blood Glucose < 70 mg/dL * * * p<0.05versuscontrol * p<0.05 versus control * * * *

30 Median HbA1c by Group vs. Time * p<0.05 versus control group *

31 Summary and Conclusions Biographer use was well tolerated in the home environmentBiographer use was well tolerated in the home environment HbA1c was significantly lower (p<0.05) in the Biographer treatment group compared to the control group after 3 months of treatmentHbA1c was significantly lower (p<0.05) in the Biographer treatment group compared to the control group after 3 months of treatment Biographer users detected significantly more hypoglycemia during the day and night than non- usersBiographer users detected significantly more hypoglycemia during the day and night than non- users The Biographer is useful for improving glucose control and detecting hypoglycemia in children and adolescents with type 1 diabetesThe Biographer is useful for improving glucose control and detecting hypoglycemia in children and adolescents with type 1 diabetes

32 Using DCCT data, a decline in HbA1c from 9.0 to 8.4 for 100 subjects for a lifetime would: 1) 1)Prevent severe eye disease in 20 people 2) 2)Prevent blindness in 6 people 3) 3)Prevent gross kidney damage in 20 people (8 needing transplants) 4) 4)Prevent 6 cases of neuropathy Reduction in Complications: Eastman RC, Chase HP and Leptien AD Pediatric Diabetes 4:82-86, 2003

33 Slept through alarms Picked up low at calibration 0733 BG GWB tracings Pre-teen girl IDDM x 5yrs Patient at slumber party 2008 BG 56 4/18 4/194/ BG BG 259

34 4/25 5/ bg Piano teacher gave candy but did not test 1357 bg175 Pre-teen girl IDDM x 5yrs 0908 bg bg45 Went to office No snack given Low alarm at same time as last week (1530) No bg test 1759 bg bg80

35 Part IV: DIRECNET STUDY GROUP DIabetes REsearch in Children NETwork i)NIH funded collaborative study group (NICHD and NIDDK) ii)5 Centers: Denver, Iowa, Nemours (FL), Stanford and Yale. + Coordinating Center: = Jaeb Center for Health Research, Tampa, FL

36 DIRECNET STUDY GROUP DIRECNET STUDY GROUP iii) Objective = to critically evaluate the clinical usefulness of current and future glucose sensors in youth with T1DM. iv) Initial inpatient study= accuracy of G2B and of CGMS. Abstracts #156 OR, #432-P and #387-P. v) Next study: Similar to the GWB Pilot Trial done in Denver, but with 200 children x 6 months.

37 Part V: SUMMARY Purpose of the GlucoWatch Biographer: To detect trends and to track patterns in glucose levels as a supplement to SMBG (not to replace SMBG). Conclusion: The level of accuracy is sufficient for detecting trends. Pilot data shows the GWB is useful for improving glycemic control and detecting hypoglycemia in children and adolescents with T1DM.